As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Moleculin Biotech, Inc. The largest reported stake is CVI Investments, Inc.'s, at 9.9%. 5 filings are on record since August 14, 2025 (Schedule 13G, August 10, 2026).
Sell to companies like Moleculin Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Klemp Walter V · Sole voting: 2,070,761 · Shared voting: 0 · Sole dispositive: 2,070,761 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-25
- · Reporting person: Foster Jonathan P. · Sole voting: 1,288,207 · Shared voting: 0 · Sole dispositive: 1,288,207 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-25
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 1,863,377 · Sole dispositive: 0 · Shared dispositive: 1,863,377 · SCHEDULE 13G, 2026-08-10
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 973,927 · Sole dispositive: 0 · Shared dispositive: 948,927 · SCHEDULE 13G, 2026-08-06
- · Holder: Armistice Capital, LLC · Percent: 4.99% · SCHEDULE 13G/A
Moleculin Biotech, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CVI Investments, Inc. | 9.9% | 1,863,377 | SCHEDULE 13G, 2026-08-10 | 2026-07-31 |
| 9.9% | 2,070,761 | SCHEDULE 13D, 2026-08-25 | 2026-08-19 | |
| 6.3% | 1,288,207 | SCHEDULE 13D, 2026-08-25 | 2026-08-19 | |
| Armistice Capital, LLC | 4.99% | 1,586,521 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 4.99% | 973,927 | SCHEDULE 13G, 2026-08-06 | 2026-07-31 |
Holding shares or following this stake? See who's behind Moleculin Biotech, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Moleculin Biotech, Inc. and the records around it.
Moleculin Biotech, Inc. elsewhere on the record
Companies that share a holder
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Moleculin Biotech, Inc.
Get an email when Moleculin Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Moleculin Biotech, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Moleculin Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Moleculin Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| CVI Investments, Inc. | 0 | 1,863,377 | 0 | 1,863,377 | SCHEDULE 13G, 2026-08-10 |
| Heights Capital Management, Inc. | 0 | 1,863,377 | 0 | 1,863,377 | SCHEDULE 13G, 2026-08-10 |
| Klemp Walter V | 2,070,761 | 0 | 2,070,761 | 0 | SCHEDULE 13D, 2026-08-25 |
| AnnaMed, Inc. | 636 | 0 | 636 | 0 | SCHEDULE 13D, 2026-08-25 |
| Foster Jonathan P. | 1,288,207 | 0 | 1,288,207 | 0 | SCHEDULE 13D, 2026-08-25 |
| Mitchell P. Kopin | 0 | 973,927 | 0 | 948,927 | SCHEDULE 13G, 2026-08-06 |
| Daniel B. Asher | 0 | 973,927 | 0 | 948,927 | SCHEDULE 13G, 2026-08-06 |
| Intracoastal Capital LLC | 0 | 973,927 | 0 | 948,927 | SCHEDULE 13G, 2026-08-06 |
The latest filing identifies Moleculin Biotech, Inc. by CUSIP 60855D408 and gives its principal executive office as 5300 MEMORIAL DRIVE, SUITE 950, HOUSTON, TX 77007 (SCHEDULE 13D, 2026-08-25).
Source of funds (Item 3)
Mr. Klemp acquired the shares of Common Stock and the Common Warrants reported herein pursuant to a public offering by the Issuer, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. The offering was made pursuant to a Registration Statement on Form S-1 (File No. 333-297776), which was declared effective on July 31, 2026, and was conducted through Roth Capital Partners, LLC as placement agent. In connection with the offering, Mr. Klemp entered into a Securities Purchase Agreement with the Issuer, pursuant to which Mr.Klemp Walter V, SCHEDULE 13D, 2026-08-25
Mr. Foster acquired the shares of Common Stock and the Common Warrants reported herein pursuant to a public offering by the Issuer, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. The offering was made pursuant to a Registration Statement on Form S-1 (File No. 333-297776), which was declared effective on July 31, 2026, and was conducted through Roth Capital Partners, LLC as placement agent. In connection with the offering, Mr. Foster entered into a Securities Purchase Agreement with the Issuer, pursuant to which Mr.Foster Jonathan P., SCHEDULE 13D, 2026-08-25
Purpose of Transaction (Item 4)
Klemp Walter V
On August 3, 2026, Mr. Klemp purchased 533,333 shares of Common Stock and Common Warrants to purchase up to 1,599,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors. Except as set forth in this Schedule 13D, the Reporting Persons do not have any plan or proposal that would relate to, or result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-25; the filing has the rest
Foster Jonathan P.
On August 3, 2026, the Reporting Person purchased 293,333 shares of Common Stock and Common Warrants to purchase up to 879,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors. Except as set forth in this Schedule 13D, the Reporting Person does not have any plan or proposal that would relate to, or result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or of any of its subsidiaries; (d) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-25; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-08-06 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-08-10 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2026-08-25 | Klemp Walter V | 9.9% | SCHEDULE 13D |
| 2026-08-25 | Foster Jonathan P. | 6.3% | SCHEDULE 13D |
Questions about who owns Moleculin Biotech, Inc.
Who owns Moleculin Biotech, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Moleculin Biotech, Inc.: CVI Investments, Inc. (9.9%, Schedule 13G, filed 2026-08-10), Klemp Walter V (9.9%, Schedule 13D, filed 2026-08-25) and Foster Jonathan P. (6.3%, Schedule 13D, filed 2026-08-25).
Who are the largest shareholders of Moleculin Biotech, Inc.?
By the share each holder's latest filing reports, the largest holders of Moleculin Biotech, Inc. on this page are CVI Investments, Inc. (9.9%), Klemp Walter V (9.9%) and Foster Jonathan P. (6.3%).
When did CVI Investments, Inc. buy into Moleculin Biotech, Inc.?
The filings give report dates, not purchase dates. The earliest filing from CVI Investments, Inc. on this page is the Schedule 13G, filed 2026-08-10, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Moleculin Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.